Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (NCT06096844)
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
Age range: 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (324 Sites)
Showing the first 25 of 324 sites.
- Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- Highlands Oncology Group - Rogers — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente-Oakland — Oakland, California
- VA Palo Alto Health Care System — Palo Alto, California
- Kaiser Permanente-Roseville — Roseville, California
- Kaiser Permanente Downtown Commons — Sacramento, California
- Kaiser Permanente-South Sacramento — Sacramento, California
- Kaiser Permanente-San Francisco — San Francisco, California
- Kaiser Permanente-Santa Teresa-San Jose — San Jose, California
- Kaiser Permanente San Leandro — San Leandro, California
- Kaiser San Rafael-Gallinas — San Rafael, California
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara, California
- Kaiser Permanente-Santa Rosa — Santa Rosa, California
- Kaiser Permanente-South San Francisco — South San Francisco, California
- Kaiser Permanente-Vallejo — Vallejo, California
- Kaiser Permanente-Walnut Creek — Walnut Creek, California
- Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
📞 Contact the Study Coordinator
Phone: (479) 872-8100
Email: research@hogonc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Lung Non-Small Cell Carcinoma
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer — Birmingham, Alabama
- Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors — Orange, California
- Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) — Birmingham, Alabama
- Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer — Duarte, California
- CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer — Buffalo, New York
- Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer — Duarte, California
Explore by condition: All Advanced Lung Non-Small Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.